POSTED ON
OCTOBER 4, 2017

Company Clinical Trials

Purpose: The company researched and developed a true full spectrum of antibodies targeting over 20 pathogens in one dose. We decided on making multiple kinds of antibodies for multiple kinds of pathogens and diseases including: salmonella, e-coli, c-difficile, campylobacter, influenzas, IBR, BVD, Leptospira, and others. The purpose was to see if we could replace the use of vaccines in the dairy industry. So a major clinical trial was needed to see if in "real life" it was possible to treat or prevent multiple diseases without using any vaccines and to see if we could replace the whole animal immunization program with a complete and multiple antibody immunity packages for all barnyard diseases.

As our antibodies are preserved to keep 100% activity it was then decided that if we could prevent and treat all these diseases in dairy herds with antibodies that have no expiry date, then our antibody packages could work on the diseases of people, but especially for those who live in areas where special handling and refrigeration were problematic. That would become our second trial.

The trials were overseen by a veterinarian, cattle handler and the Founder of the technology and products.

Animal Herds Used

Trials were conducted in the State of California using 60 Holstein calves from the herd of approximately 17,000. The reason why calves were used is that they are born without any immunity. Therefore this would be an ideal group to target with each and every calf in both groups starting with “zero” immunity. They were then separated into two groups, Group A and B, with 30 newborn calves, in each group.

How Treatment was Administered

Each calf in Group A received 1 liter of our concentrated IgGs product Bridge and a nasal spray treatment at birth. However, Group B received its mother’s colostrum plus 6 injections of required vaccines at birth with one nasal spray treatment. Thereafter Group B continued to follow the regular feed and supplement program, using a superior brand name of American Supplement, recommended by California State. After receiving the first liter of Bridge, Group A received 6 grams of Bridge (product name for our cattle antibody immunity package) each day, while also receiving the regular feed. The only supplement given Group A was Bridge. Monte Question. Was a nasal spray used every day? Weren’t the trials for 6 months?

Immediate Results While Group B received all its vaccinations to prevent cases of diarrhea and leading diseases, and while still adhering to the State recommended vaccination program throughout the first 6 months, Group A calves received not a single vaccine. However, Group B continued to lose weight and had frequent cases of diarrhea. Group A, on the other hand, had no sickness at all and were gaining weight.

Long-Term Results Apart from being a complete healthier group of calves in Group A yet concerning the weight of both Groups, Group A had gained 5 more US pounds than Group B after 60 days. At this point, it was clear to determine that our antibody immunity package targeted at all barnyard diseases was able to prevent and treat all barnyard diseases in real life situations. were completely eradicated by our product Bridge.

Furthermore that after 60 days the vaccine and feed supplement not only proved ineffective to prevent especially cases of diarrhea, they did not produce a disease-free environment. After the 60 days trials, a continuation of observation trials was extended to monitor the regular health of the animals for 6 months. In Group A, no other sicknesses or diseases were found in them and were completely healthy.

Overview of Trials The trials proved that Bridge's antibody immunity package could replace all 50 States vaccination program in real life situations. Secondly that animals using Bridge products could raise cattle at a lower cost, not only because the cost of the product, but also due to any loss of life, food, time to raise animals who then got sick and died. Additionally, extra maintenance costs for vet care or further medicines, treatments or supplements were not needed. While still caring for herds, less time was required to attend to the sick or weaker animals. Additionally, as calves weighed more, this would address the question of producing veal more quickly in beef cattle.

In subsequently eliminating all barnyard diseases in the dairy cows or bovine, we were able to now control two other age-old diseases of Mastitis and Failure of Passive Transfer and could

prevent the use antibiotics and antimicrobials, by eliminating them out of the immunization health care program for cows.

Human Trials* Trials Overview The dairy cow trials were obviously a huge success in determining if we could replace the animal vaccine immunization program. As to the ability to control human diseases, while still addressing the questions of safety, efficacy, potency and product quality control, batch after batch, we would obviously need to conduct trials on humans. This trial would indicate that we could also treat multiple enteric pathogens or diseases as participants had suffered enteric trouble for some time with first E-Coli, then Salmonella, and then Cholera and finally Dysentery.

Safety Trials The first thing on our list of priorities for the human trials was the issue of safety. This was the priority. Secondly, in addition to the safety trial, we wanted to establish efficacy, potency, and quality of the product. Lastly, was it possible to establish at least partially, or completely, that we could treat several diseases with one dose of our product?

There have been thousands of case studies conducted globally and for decades using regular and/or hyper-immunized colostrum and even whey based milk products containing some or a percentage of bovine antibodies and or even chicken egg antibodies.

However, we wanted to establish in our own independent trials whether our bovine and egg antibody mixture containing a variety of hyper-immunized bovine and egg antibodies would be able to prevent and/or treat the above-mentioned types of diseases. Again our immunity packages would contain antibodies that would target various pathogens targeting

multiple diarrheas, flu, common cold, pneumonia as well as: salmonella, e-coli, c-difficile, campylobacter, rhinovirus, H1N1 influenza, Rotavirus, Leptospira, and others. The purpose was to see if the product was safe enough for humans. If so, we could replace the use of vaccines in the human industry by first establishing safety.

Human Particpants Used Although this trial was overseen by an independent company who wanted to use our product as a medical food, we wanted to establish safety and establish any efficacy. Because our product contains multiple antibodies targeting multiple pathogens or diseases, the trials took place in New Dehli, India with participants who were seriously ill with enteric diseases for months. They had received various treatments to help prevent mortality with antibiotics as the last resort effort to restore their health. After antibiotics were administered the participants were given 24 hours to live. Just before being put to sleep they each received a portion of our immunity package and were given the night to recover. In fact, there was no reason to believe they'd survive so these safety trials were used in compassionate use (or 'usa expression' see SAP FILES) in 20 Indian children. They were expected not to survive the night.

Trials Results Administration of product was given to the children in the evening. Upon waking up we were told that all the children were either up eating, playing or running around. This certainly proved that the product was safe. Even life-saving. Especially with all 20 children up and active. Unfortunately, little information was given after that, except an unfinished chart containing some numbers. For years we tried to contact the company. If you'd like to receive more info please contact us.

*This trial lead to another multi-million dollar investment by the third party company that conducted the trials independently for us. The previous public company gets a percentage of all sales originating from the sales from a medical food it sells.

Future Trials Upon funding, we will begin phase 1 trials as product safety has been proven.